|
Clinical characteristics of patients |
|||
| Characteristic |
Low FcγRIIa |
High FcγRIIa |
|
| n (%) |
n (%) |
p value |
|
|
|
|||
| Age (mean ± SD) |
67 ± 15 |
67 ± 12 |
1 |
| male |
8 (50%) |
10 (63%) |
0.87 |
| CAD |
11 (71%) |
10 (63%) |
0.82 |
| CVA/TIA |
2 (12%) |
7 (44%) |
0.15 |
| Hypertension |
13 (76%) |
16 (100%) |
0.55 |
| Diabetes |
10 (61%) |
10 (63%) |
0.89 |
| Hyperlipidemia |
11 (65%) |
9 (56%) |
0.57 |
| Treatment with |
|||
| aspirin |
9 (53%) |
11(69%) |
0.89 |
| warfarin |
3 (18%) |
3 (19%) |
0.71 |
| thienopyridine |
3 (18%) |
5 (31%) |
0.64 |
| β blocker |
8 (47%) |
11 (69%) |
0.36 |
| Calcium blocker |
7 (41%) |
5 (31%) |
0.81 |
| ACEI/ARB |
7 (41%) |
4 (25%) |
0.55 |
| insulin |
5 (29%) |
7 (44%) |
0.59 |
| oral hypoglycemic |
3 (18%) |
3 (19%) |
0.71 |
| Duration of HD (mo – mean ± SD) |
31 ± 25 |
32 ± 23 |
0.91 |
|
CAD = coronary arterial disease, CVA = cerebrovascular accident, TIA = transient ischemic attack, ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, HD = hemodialysis, mo = month | |||
Serrano et al. Thrombosis Journal 2007 5:7 doi:10.1186/1477-9560-5-7 |
|||